SUDEEPPHRM — Sudeep Pharma Balance Sheet
0.000.00%
- IN₹113.03bn
- IN₹113.48bn
- IN₹6.39bn
Annual balance sheet for Sudeep Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 215 | 133 | 141 | 519 | 1,146 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,188 | 1,268 | 1,690 | 2,178 | 2,721 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,962 | 2,300 | 2,754 | 4,241 | 6,240 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,459 | 1,838 | 2,246 | 2,773 | 4,469 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 3,450 | 4,201 | 5,139 | 7,172 | 11,749 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,475 | 1,708 | 1,373 | 1,748 | 2,020 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 1,822 | 1,968 | 1,579 | 2,241 | 2,915 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1,628 | 2,233 | 3,560 | 4,931 | 8,833 |
| Total Liabilities & Shareholders' Equity | 3,450 | 4,201 | 5,139 | 7,172 | 11,749 |
| Total Common Shares Outstanding |